17 completed, 3 terminated, 1 unknown, 1 withdrawn. 22 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 17, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism Paricalcitol, Placebo - Secondary Hyperparathyroidism | Phase 3 | Unknown | Chengdu Suncadia Medicine Co., Ltd. | 84 | 2022-02-01 | 2022-02-10 |
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) Paricalcitol - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | Phase 3 | Terminated | AbbVie | 2 | 2020-09-16 | 2026-06-15 |
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 CTAP101 Capsules, Calcitriol, Doxercalciferol - Chronic Kidney Disease, Hyperparathyroidism, Secondary | Phase 3 | Completed | OPKO Health, Inc. | 298 | 2013-04-01 | 2016-09-29 |
| Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria Paricalcitol - Proteinuria | Phase 3 | Completed | Oslo University Hospital | 77 | 2013-01-01 | 2016-03-30 |
| Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients Paricalcitol, Paricalcitol, atorvastatin, Atorvastatin - Chronic Kidney Disease | Phase 3 | Completed | Ricardo Mouzo Mirco | 31 | 2012-08-01 | 2018-08-24 |
| Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients Paricalcitol, Placebo - Disorder of Transplanted Kidney, Proteinuria | Phase 3 | Completed | University Medical Centre Ljubljana | 168 | 2012-07-01 | 2017-12-27 |
| A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis paricalcitol - End-Stage Renal Disease, Secondary Hyperparathyroidism | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 13 | 2011-10-01 | 2018-07-02 |
| Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism paricalcitol, maxacalcitol, paricalcitol placebo - Secondary Hyperparathyroidism, Hemodialysis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 255 | 2011-05-01 | 2013-06-06 |
| Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease Zemplar - Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Danderyd Hospital | 36 | 2010-09-01 | 2013-09-05 |
| Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery Paricalcitol, Cholecalciferol, Placebo - Gastric Bypass, Parathyroid Hormone | Phase 3 | Completed | Kerstyn C. Zalesin, M.D. | 49 | 2010-07-01 | 2017-03-22 |
| Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) Paricalcitol, Placebo - Chronic Kidney Disease Stage 3 and 4 | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 47 | 2010-02-01 | 2018-07-02 |
| Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease paricalcitol, placebo - Coronary Artery Disease, Chronic Kidney Disease | Phase 3 | Terminated | Thomas Jefferson University | 10 | 2010-01-01 | 2014-05-20 |
| Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease paricalcitol - Chronic Kidney Disease | Phase 3 | Completed | Abbott | 216 | 2009-11-01 | 2012-01-26 |
| The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL - Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | Phase 3 | Terminated | Abbott | 12 | 2009-01-01 | 2012-01-20 |
| The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 227 | 2008-02-01 | 2013-03-12 |
| Paricalcitol for the Treatment of Immunoglobulin A Nephropathy paricalcitol - IgA Nephropathy | Phase 3 | Withdrawn | Chinese University of Hong Kong | 2008-01-01 | 2015-08-03 | |
| Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Paricalcitol, Placebo - Hypophosphatemia, Familial, Hyperparathyroidism | Phase 3 | Completed | Yale University | 33 | 2007-01-01 | 2020-03-17 |
| Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis Zemplar Capsule - Kidney Disease | Phase 3 | Completed | Abbott | 78 | 2004-08-01 | 2011-01-19 |
| Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) paricalcitol - Renal Insufficiency, Chronic | Phase 3 | Completed | Abbott | 68 | 2002-02-01 | 2006-08-15 |
| Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) paricalcitol - Renal Insufficiency, Chronic | Phase 3 | Completed | Abbott | 68 | 2002-02-01 | 2006-08-02 |
Showing 20 of 22. Sign in to see all of them.
Renal Insufficiency, Chronic (13) · Hyperparathyroidism, Secondary (7) · Hyperparathyroidism (3) · Kidney Failure, Chronic (3) · Albuminuria (2) · Hypertrophy, Left Ventricular (2) · Kidney Diseases (2) · Proteinuria (2) · Vitamin D Deficiency (2) · Coronary Artery Disease (1) · Familial Hypophosphatemic Rickets (1) · Glomerulonephritis, IGA (1) · Hypophosphatemia (1) · Hypophosphatemia, Familial (1) · Parathyroid Diseases (1)
Abbott (7) · AbbVie (prior sponsor, Abbott) (4) · AbbVie (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Chinese University of Hong Kong (1) · Danderyd Hospital (1) · Kerstyn C. Zalesin, M.D. (1) · OPKO Health, Inc. (1) · Oslo University Hospital (1) · Ricardo Mouzo Mirco (1) · Thomas Jefferson University (1) · University Medical Centre Ljubljana (1) · Yale University (1)
United States (11) · Poland (6) · Puerto Rico (3) · Spain (3) · Australia (2) · Czechia (2) · Germany (2) · Italy (2) · Romania (2) · Russia (2) · Taiwan (2) · United Kingdom (2) · China (1) · Greece (1) · Hong Kong (1)
Laura Williams, M.D. (3) · Ann Eldred, MD (2) · Cheuk Chun Szeto, MD (1) · David J Whellan, MD MHS (1) · Deepa Chand, MD (1) · Dennis Andress, MD (1) · Hallvard Holdaas, MD, PhD (1) · Joel Melnick, MD (1) · Kazuya Kobayashi, BA (1) · Kerstyn Zalesin, MD (1) · Laura A Williams, M.D., MPH (1) · Miha Arnol, M.D., Ph.D. (1) · Ricardo Mouzo Mirco, MD (1)
PMID 18591942, PMID 28332096, PMID 21242674, PMID 22337679, PMID 23194491, PMID 25029424, PMID 26496210, PMID 28511692, PMID 30062716, PMID 30134956, PMID 31370809, PMID 33326471
P50AR054086 (1)